Everolimus-induced pneumonitis in neuroendocrine neoplasms: correlation of CT findings and clinical signs

Background Everolimus, a mammalian target of rapamycin (mTOR)-inhibitor, is approved for the treatment of advanced neuroendocrine neoplasms (NEN). A rare major adverse event is the occurrence of drug-induced pneumonitis. Purpose To evaluate the correlation between clinical signs and computed tomography (CT) findings in everolimus-induced pneumonitis in patients with NEN. Material and Methods Ninety patients with NEN treated with everolimus were...